95 related articles for article (PubMed ID: 21273612)
1. A phase II study of weekly paclitaxel and doxifluridine combination chemotherapy for advanced/recurrent gastric cancer.
Takeyoshi I; Makita F; Tanahashi Y; Iwazaki S; Ogawa T; Tomizawa N; Nakamura S; Ishikawa H; Ohya T; Kakinuma S; Nakagami K; Sato Y; Koyano T; Roppongi T; Izumi M; Kobayashi J; Kawate S; Sunose Y; Kobayashi M; Yamada T; Sakamoto I
Anticancer Res; 2011 Jan; 31(1):287-91. PubMed ID: 21273612
[TBL] [Abstract][Full Text] [Related]
2. Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Takiuchi H; Goto M; Imamura H; Furukawa H; Imano M; Imamoto H; Kimura Y; Ishida H; Fujitani K; Narahara H; Shimokawa T
Jpn J Clin Oncol; 2008 Mar; 38(3):176-81. PubMed ID: 18281707
[TBL] [Abstract][Full Text] [Related]
3. Combination phase II study of weekly paclitaxel and 5'-DFUR for unresectable or recurrent gastric cancer.
Yoshino S; Furuya T; Shimizu R; Ozasa H; Nishimura T; Fukuda S; Kawaoka T; Hazama S; Oka M
Anticancer Res; 2013 Jun; 33(6):2629-33. PubMed ID: 23749919
[TBL] [Abstract][Full Text] [Related]
4. Weekly paclitaxel in combination with doxifluridine for peritoneally disseminated gastric cancer with malignant ascites.
Takeyoshi I; Makita F; Iwazaki S; Ishikawa H; Kakinuma S; Sato Y; Ohya T; Nakagami K; Tomizawa N; Izumi M; Kobayashi I; Tanahashi Y; Kobayashi J; Kamoshita N; Kawate S; Sunose Y; Sakamoto I; Yoshinari D; Yamada T; Okabe T
Anticancer Res; 2011 Dec; 31(12):4625-30. PubMed ID: 22199340
[TBL] [Abstract][Full Text] [Related]
5. [Combined chemotherapy with weekly Paclitaxel and doxifluridine for advanced and recurrent gastric cancers].
Mizutani S; Oyama T; Hatanaka N; Uchikoshi F; Yoshidome K; Tori M; Ueshima S; Okuma K; Hiraoka K; Yamagami Y; Takahashi H; Sueyoshi K; Taira M; Nakahara M; Nakao K
Gan To Kagaku Ryoho; 2006 Mar; 33(3):327-31. PubMed ID: 16531712
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
[TBL] [Abstract][Full Text] [Related]
7. [Experience of weekly paclitaxel combined with orally administered doxifluridine therapy for advanced and recurrent gastric cancer-preliminary study].
Tsubono M; Kaneko I; Kii E; Murata T; Kamimura K; Deguchi Y; Yasumizu R
Gan To Kagaku Ryoho; 2005 Sep; 32(9):1283-7. PubMed ID: 16184925
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer].
Okamoto Y; Tominaga T; Okuyama N; Sawada T; Kou Y
Gan To Kagaku Ryoho; 2003 May; 30(5):661-7. PubMed ID: 12795098
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer.
Yeh KH; Lu YS; Hsu CH; Lin JF; Hsu C; Kuo SH; Li SJ; Cheng AL
Oncology; 2005; 69(1):88-95. PubMed ID: 16088236
[TBL] [Abstract][Full Text] [Related]
11. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial.
Nishimura R; Tominaga T; Kimura M; Yanagita Y; Tamaki N; Asaishi K; Okamoto Y; Okuyama N; Takeuchi H; Inaba M; Doi T
Anticancer Drugs; 2008 Oct; 19(9):911-5. PubMed ID: 18766005
[TBL] [Abstract][Full Text] [Related]
13. A combination phase I study of weekly paclitaxel and doxifluridine in advanced gastric cancer patients.
Takeyoshi I; Makita F; Tanahashi Y; Yokomori T; Iwazaki S; Kawashima Y; Iwanami K; Yamada T; Kawate S; Hamada K; Sunose Y; Yoshida M; Horiguchi J; Iesato H; Kobayashi M; Morishita Y
Anticancer Res; 2005; 25(2B):1291-6. PubMed ID: 15865080
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of weekly paclitaxel and cisplatin combination therapy for advanced or recurrent gastric cancer.
Nagata N; Kimura M; Hirabayashi N; Tuburaya A; Murata T; Kondo K; Fukuda Y; Kobayashi M; Miyashita Y; Nakao A; Sakamoto J
Hepatogastroenterology; 2008; 55(86-87):1846-50. PubMed ID: 19102406
[TBL] [Abstract][Full Text] [Related]
16. Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1.
Arai W; Hosoya Y; Hyodo M; Haruta H; Kurashina K; Saito S; Hirashima Y; Yokoyama T; Zuiki T; Sakuma K; Yasuda Y; Nagai H
Int J Clin Oncol; 2007 Apr; 12(2):146-9. PubMed ID: 17443283
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancer.
Moriwaki T; Hyodo I; Nishina T; Hirao K; Tsuzuki T; Hidaka S; Kajiwara T; Endo S; Nasu J; Hirasaki S; Masumoto T; Kurita A
Cancer Chemother Pharmacol; 2005 Aug; 56(2):138-44. PubMed ID: 15827767
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Ueda Y; Yamagishi H; Ichikawa D; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Takenaka A; Yamashita T; Kurioka H; Nishiyama M; Morita S; Nakamura K; Sakamoto J
Oncology; 2005; 69(3):261-8. PubMed ID: 16138002
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of doxifluridine (5'-DFUR)/docetaxel against advanced/recurrent gastric cancer showing resistance to various anticancer drug regimens.
Sato A; Shimada K; Nakamachi M; Ushio J; Yamamoto W; Kurihara M; Matsukawa M
Gastric Cancer; 2002; 5(4):233-6. PubMed ID: 12491082
[TBL] [Abstract][Full Text] [Related]
20. [Bi-weekly docetaxel and doxifluridine combination therapy in pretreated patients with unresectable and/or advanced gastric cancer].
Nukaya H; Kajino S; Tokuda H; Tanaka Y; Hasegawa I; Kato A; Joh T
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1713-7. PubMed ID: 20841933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
